%0 Journal Article
%A Sachpekidis, Christos
%A Kopp-Schneider, Annette
%A Hassel, Jessica C
%A Dimitrakopoulou-Strauss, Antonia
%T Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study.
%J EJNMMI Research
%V 11
%N 1
%@ 2191-219X
%C Heidelberg
%I Springer
%M DKFZ-2021-02000
%P 89
%D 2021
%Z #EA:E060#LA:E060#
%X The usage of immune checkpoint inhibitors (ICIs) is the standard practice for the treatment of metastatic melanoma. However, a significant amount of patients show no response to immunotherapy, while issues on its reliable response interpretation exist. Aim of this study was to investigate the phenomenon of early disease progression in 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in melanoma patients treated with ICIs.Thirty-one patients under ICIs serially monitored with 18F-FDG PET/CT were enrolled. All patients exhibited progressive metabolic disease (PMD) after two ICIs' cycles according to the European Organization for Research and Treatment of Cancer (EORTC) criteria, and were characterized as unconfirmed PMD (uPMD). They were further followed with at least one PET/CT for either confirmation of PMD (cPMD) or demonstration of pseudoprogression remission. Patients were also evaluated with the PET Response Evaluation Criteria for Immunotherapy (PERCIMT). Moreover, in an attempt to investigate immune activation, the spleen to liver ratios (SLRmean, SLRmax) of 18F-FDG uptake were measured.Median follow up was 69.7 months [64.6-NA]. According to EORTC, 26/31 patients with uPMD eventually showed cPMD (83.9
%K 18F-FDG PET/CT (Other)
%K Confirmed progressive disease (Other)
%K Immunotherapy (Other)
%K Metastatic melanoma (Other)
%K Pseudoprogression (Other)
%K Spleen glucose metabolism (Other)
%K Unconfirmed progressive disease (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34495433
%R 10.1186/s13550-021-00832-4
%U https://inrepo02.dkfz.de/record/170546